Cedars-Sinai Biomanufacturing

Los Angeles, CA
National Center
Cell Therapy Gene Editing
30 confirmed programs · 16 sponsors · Last scored 2026-03-15
63.0
Signal Score
✓ FDA Inspections (1) ✓ Clinical Trials (30) ○ SEC Filings ○ Press

Quick Facts: Cedars-Sinai Biomanufacturing

Signal Score
63.0/100 (as of 2026-03-15)
Quality Compliance
Assessment pending
Headquarters
Los Angeles, CA
Modalities
Cell Therapy, Gene Editing
Active CGT Programs
30 confirmed from ClinicalTrials.gov across 16 sponsors
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CGT manufacturing intelligence platform

Signal Score & Pillar Breakdown

Quality Compliance —
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA Inspections1 on record
Warning Letters0
Last InspectionNo Action Indicated (NAI) (2025-03-14)
Operations —
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs 30
Sponsors16
ModalitiesCell Therapy, Gene Editing
30 active programs across 16 sponsors
Modalities: Gene Editing, Cell Therapy
12 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov facility matching
NCT06208878 A Long-term Follow-up Study of Subjects Who Received CRISPR... NA Enrolling By Invitation
NCT05781152 Clinical, Imaging, and Endoscopic Outcomes of Children Newly... PHASE4 Recruiting
NCT05819359 Efficacy, Safety, Tolerability, Pharmacodynamics, and... PHASE2 Active Not Recruiting
NCT05306457 CNS10-NPC-GDNF Delivered to the Motor Cortex for ALS PHASE1 Active Not Recruiting
NCT04284293 CNS10-NPC for the Treatment of RP PHASE1 Active Not Recruiting
NCT04681131 CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC PHASE2 Completed
NCT04669899 Study of JTX-8064, as Monotherapy and in Combination With a... PHASE1/PHASE2 Completed
NCT03751709 Blinatumomab Plus HLA-Mismatched Cellular Therapy for... PHASE1 Completed
NCT04224558 Stem Cell Transplantation in Crohn's Disease PHASE1/PHASE2 Recruiting
NCT04035434 A Safety and Efficacy Study Evaluating CTX110 in Subjects... PHASE1/PHASE2 Terminated
View all 30 programs →
Source: ClinicalTrials.gov · Retrieved Mar 20, 2026
Financial Stability 68.0
Parent company: Cedars-Sinai Medical Center
Financial assessment: 68.0/100
Source: SEC EDGAR, press monitoring
Subsidiary of Cedars-Sinai Medical Center
SEC FilingsParent: Cedars-Sinai Medical Center
Parent company: Cedars-Sinai Medical Center
Financial assessment: 68.0/100
Capacity 58.0
1 CGT manufacturing site: Los Angeles, CA
Modalities: Cell Therapy, Gene Editing
Capacity assessment: 58.0/100
Sites: Los Angeles, CA
Source: SEC EDGAR, press monitoring, company profiles
1 CGT manufacturing site
1 CGT manufacturing site: Los Angeles, CA
Modalities: Cell Therapy, Gene Editing
Capacity assessment: 58.0/100

FDA Inspection History

2025-03
NAI VAI OAI
Date Site Type Observations Classification
2025-03-14 West Hollywood, California Blood and Blood Products No No Action Indicated (NAI)
Source: FDA Data Dashboard · Retrieved Mar 20, 2026

Clinical Activity 30 studies

NCT06208878 A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies NA Enrolling By Invitation NCT05781152 Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With... PHASE4 Recruiting NCT05819359 Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of... PHASE2 Active Not Recruiting NCT05306457 CNS10-NPC-GDNF Delivered to the Motor Cortex for ALS PHASE1 Active Not Recruiting NCT04284293 CNS10-NPC for the Treatment of RP PHASE1 Active Not Recruiting NCT04681131 CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC PHASE2 Completed NCT04669899 Study of JTX-8064, as Monotherapy and in Combination With a PD-1 Inhibitor,... PHASE1/PHASE2 Completed NCT03751709 Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+ ALL PHASE1 Completed NCT04224558 Stem Cell Transplantation in Crohn's Disease PHASE1/PHASE2 Recruiting NCT04035434 A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or... PHASE1/PHASE2 Terminated NCT04048577 A Pilot Study to Characterize the Biological Effect of a Pre-planned 12 Week... PHASE4 Unknown NCT03859388 Longitudinal Changes in Donor-Derived Cell-Free DNA With Tocilizumab... NA Active Not Recruiting NCT03508609 Safety and Potential Bioactivity of CLBS16 in Patients With Coronary... PHASE2 Completed NCT03145298 ALlogeneic Cardiosphere-derived Stem Cells (CDCs) for Pulmonary Hypertension therApy PHASE1 Completed NCT02943850 CNS10-NPC-GDNF for the Treatment of ALS PHASE1 Completed NCT02684006 A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell... PHASE3 Completed NCT02574390 Answer ALS: Individualized Initiative for ALS Discovery NA Completed NCT02534376 Cellular Effect of Cholesterol-Lowering Prior to Prostate Removal EARLY_PHASE1 Completed NCT01496209 REgenerative CardiOsphere iNjection to STRengthen dysfUnCTional Hearts PHASE1 Withdrawn NCT02026271 A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or... PHASE1 Completed
+ 10 more studies
Source: ClinicalTrials.gov · Retrieved Mar 20, 2026
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Cell Therapy CDMOs → Gene Editing CDMOs →